نفساني - عرض مشاركة واحدة

23-09-2017, 05:07 PM

الايبكسا و رغم انه من المفترض ان يحسن التركيز فإنه معي حسن الدافعية اكثر من التركيز..كان هدف الطبيبة التي وصفت لي اياه للتركيز اكثر..
الاعراض الجانبية عندما اخذت اي جرعة اعلى "وصلت الى 50" اول يومين اشعر بنعاس بعدها يذهب هذا الشعور..
انا اخذ 50 لوجود كمية كبيرة عندي و لأن هناك تجارب علمية وصلت الى هذا التركيز..لكن للأسف لم يحدث اي فائدة اضافية بعد تعدي جرعة20
يقول عدد من المجربين ان اخذ المغنسيوم مع الايبكسا قد حسن وضعهم اكثر في حالتي كان التحسن طفيفا

حول الجرعة فوق ال20

Like most,6, 22, 23 but not all,24 prior trials of memantine for depression, our dosing did not exceed the maximum dose approved for human use (20 mg/day). A small pilot study (n=8),24 in which 37.5% of the participants received doses of memantine of 30–40 mg/day, reported a much higher rate of treatment responders (62.5%) than either our trial (13.3%) or the placebo-controlled monotherapy trial.6 However, this 8-subject pilot study’s open-label design and requirement of prior positive response to antidepressant treatment may have considerably boosted responses independent of any effects from higher dosage. Furthermore, the decision whether to evaluate higher-than-currently-approved dosages of memantine for major depressive disorder may need to consider emerging toxicological literature reporting NMDA antagonist-associated neurotoxicity in some animal models of the developing brain. This literature which has prompted FDA hearings to discuss the relevance to human anesthetic use of NMDA antagonists, especially in children.25–27 Two major reservations concerning the relevance of these animal safety studies have been raised, the first involving the need to employ excessive doses compared to human use, and the second concerning the use of “unrealistically long” (i.e., multi-day) exposures.25 While the first reservation concerning dosing would still apply to potential psychiatric use (and it may be additionally reassuring that NMDA-antagonists are being investigated in adults, not children), the second reservation (concerning duration of exposure) potentially would not apply to likely psychiatric use of oral NMDA-antagonists.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000742/